Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report report published on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $41.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Robert W. Baird began coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They issued an outperform rating and a $26.00 price target on the stock. Truist Financial initiated coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They issued a buy rating and a $36.00 price target for the company. Oppenheimer boosted their price target on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an outperform rating in a research note on Wednesday, September 4th. Barclays increased their price objective on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an overweight rating in a research report on Monday, July 15th. Finally, Royal Bank of Canada boosted their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an outperform rating in a research report on Friday, July 12th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics has a consensus rating of Moderate Buy and an average target price of $28.71.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $25.16 on Friday. Nurix Therapeutics has a 1-year low of $4.22 and a 1-year high of $26.31. The business has a fifty day moving average price of $23.36 and a 200 day moving average price of $19.35. The stock has a market capitalization of $1.24 billion, a P/E ratio of -8.62 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The business had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. As a group, equities research analysts anticipate that Nurix Therapeutics will post -2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,408 shares of the company’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the sale, the insider now owns 45,150 shares in the company, valued at $933,250.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now owns 31,002 shares in the company, valued at approximately $781,870.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gwenn Hansen sold 3,408 shares of the stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the sale, the insider now directly owns 45,150 shares in the company, valued at approximately $933,250.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,815 shares of company stock worth $1,424,931. Insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

A number of hedge funds have recently bought and sold shares of NRIX. Redmile Group LLC lifted its position in shares of Nurix Therapeutics by 37.7% during the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after buying an additional 1,226,497 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in Nurix Therapeutics during the second quarter valued at $26,778,000. Candriam S.C.A. grew its position in shares of Nurix Therapeutics by 30.5% in the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after purchasing an additional 272,136 shares during the period. Affinity Asset Advisors LLC increased its stake in shares of Nurix Therapeutics by 12.6% during the second quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company’s stock worth $19,033,000 after purchasing an additional 101,747 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Nurix Therapeutics by 60.2% during the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock worth $12,514,000 after purchasing an additional 225,374 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.